Concinnity Genetics, based in Edinburgh, successfully secures £3 million in a funding round.
- The company focuses on novel gene therapies integrating control mechanisms for safety.
- Scottish investor Eos Advisory led the funding round, supporting pioneering science.
- Additional support from Scottish Enterprise, Old College Capital, and Maven Capital Partners.
- Concinnity aims to enhance therapeutic safety with synthetic biology and AI-machine learning.
Concinnity Genetics, an Edinburgh-based health tech company founded in 2023, has completed a significant £3 million funding round. This funding round, oversubscribed due to heightened interest, was spearheaded by Eos Advisory, a Scottish investment firm committed to supporting groundbreaking scientific advancements.
Concinnity’s innovative approach involves developing unique gene therapies with integrated control mechanisms aimed at improving the safety of gene and cell therapies. Jessica Birt, CEO and co-founder, emphasised their goal to become a leading entity in gene control, leveraging this investment to drive technology development. “This commitment from our investors, building on the ongoing support from Scottish Enterprise, speaks to the potential they see in our work,” she stated, highlighting the investors’ confidence in Concinnity’s potential.
The funding received was not solely from Eos Advisory but also included contributions from Scottish Enterprise, Old College Capital – the University of Edinburgh’s venture capital fund, and Maven Capital Partners. These investors recognise the technological potential of Concinnity, described by Eos’s Andrew McNeill as “the holy grail for emerging gene therapies”, suggesting that these new therapies could significantly enhance efficacy and safety by combining synthetic biology with AI-machine learning.
Dr Andrea Taylor, CEO of Edinburgh Innovations, pointed out the University of Edinburgh’s strengths in engineering biology, suggesting that sophisticated gene control systems could revolutionise advanced therapeutics and offer novel treatment options impacting future health. This aligns with Concinnity’s contribution to the field, which seeks to revolutionise safety in gene therapy applications through their pioneering technology.
Concinnity Genetics is poised to advance gene therapy safety through strategic funding and innovative technology.
